Slide 1: Results Presentation for the Half Year Ended 31 December 2020
For personal use only For immediate release 18 February 2021 RESULTS PRESENTATION FOR THE HALF YEAR ENDED 31 DECEMBER 2020 Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY) Please find attached the slides for the presentation on the half year results that will be given by the Chief Executive Officer
Slide 2: CSL Limited 2021 Half Year Results
For personal use only CSL Limited 2021 Half Year Results 18th February, 2021 Paul Perreault John Levy CEO and MD Interim CFO
Slide 3: Forward Looking Statements
For personal use only FORWARD LOOKING STATEMENTS The materials in this presentation speak only as of the date of these materials and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in researc
Slide 4: Highlights
Highlights1 Revenue up 15% with net profit after tax up 44% For personal use only CSL Behring Seqirus • The COVID-19 pandemic has tempered the • EBIT +24% • EBIT +112% performance of CSL • HIZENTRA® +19% • Seasonal influenza vaccines +44% Behring whilst boosting the • ALBUMIN +93% • Gross margin up
Slide 5: CSL Behring: Sales up 11%
CSL Behring Sales up 11%1 For personal use only Sales Change1 Region1 Therapy $m % Immunoglobulins 2,157 7% 2% - IVIG 1,403 2% ROW - SCIG 754 19% 79% 7% Albumin 546 93% Asia Pac 15% Haemophilia 563 1% - Recombinants 336 5% US$4.3B North America 5% - Plasma 227 (5%) 11% 50% Specialty 899 3% 4% EU 28%
Slide 6: Immunoglobulins
Immunoglobulins Sales up 7%1 For personal use only • Growth continues to be driven by chronic indications - PID, Market SID, CIDP • Strong growth in HIZENTRA® +19%1 driven by: • Global Ig demand remains strong − Preference for home treatment and innovation: – Flexible dosing • COVID-19 intensifying
Slide 7: Albumin
Albumin Sales up 93%1 For personal use only • China: Potential growth − Sales normalised following successful transition to GSP drivers − Maintained market leadership • Preference for − COVID-19 reduced hospital operations: albumin over artificial – Now returned to ~90% of ‘normal’ colloids − Increa
Slide 8: Haemophilia
Haemophilia Sales up 1%1 For personal use only • IDELVION® +6%1 − Compelling clinical profile continuing to drive patient demand Growth tempered by • AFSTYLA® sales flat1 reduced doctor − Competitive market visits during • HUMATE® +6%1 COVID-19 − Market leader in the US for vWF pandemic • Demand for
Slide 9: Specialty Products
Specialty Products Sales up 3%1 For personal use only HAE Hospital Products ALPHA-1 -7% • HAEGARDA® +16%1 • KCENTRA® +6%1 • ZEMAIRA® − New patients and • Wound healing -26%1 decline in US following patient switches • RIASTAP® flat supply interruption − New launches in EU & • RESPREEZA® Australia exc
Slide 10: Plasma Collections
Plasma Collections For personal use only CHALLENGES INITIATIVES • Plasma collections adversely • Enhanced targeted marketing initiatives to increase collections impacted by COVID-19 • Adoption of new technology • Stimulus packages in the US • Satisfy donors with a positive experience • Collection vo
Slide 11: Plasma Collections: Initiatives driving donor growth
Plasma Collections Initiatives driving donor growth For personal use only DONORS PER WEEK Annual tax season drop Holiday Season Pandemic and lockdowns begin Initiatives launched JAN FEB MAR APR MAY JUN JULY AUG SEP OCT NOV DEC 10
Slide 12: Seqirus Revenue
Seqirus Revenue Revenue up 38%1 For personal use only Therapy Sales Change1 Region1 $m % 17% QIV 669 31% Seasonal 9% TIV 22 (28%) Influenza vaccines Adjuvanted 563 70% Asia Pac +44% 6% Other / In-licence 86 5% Total Product Sales 1,340 40% EU US$1.4B Pandemic 77 4% 64% 21% Other Income 8 83% 38% Nor
Slide 13: Seqirus Operating Highlights
Seqirus Operating Highlights For personal use only • Significant growth in seasonal influenza vaccines • Record number of doses NH 20/21 >100m • Ongoing portfolio shift to differentiated products – FLUCELVAX® & FLUAD® COVID-19 • Re-launch of business in Germany pandemic • FLUAD® QIV launched in the
Slide 14: R&D Highlights
R&D Highlights For personal use only Cardiovascular & Immunology Hematology Metabolic • HIZENTRA® 5-, 10- & 20-mL pre-filled • uniQure announced data from • CSL112 (ApoA-1) Phase III study (AEGIS-II) syringes launched in US Phase III trial of EtranaDez >11,500 patients enrolled, successful completio
Slide 15: R&D: COVID-19 Response
R&D: COVID-19 Response For personal use only • Re-prioritisation of R&D • COVID-19 vaccine projects: collaborations: – Redeployment and – University of Queensland recruitment of personnel UQ 451 – significant scale – Paused and up to support Australian recommenced clinical and international trials p
Slide 16: Financials
. For personal use only Financials John Levy Interim CFO 15
Slide 17: Financial Highlights: Net Profit After Tax
Financial Highlights Net Profit After Tax For personal use only +45% $1,810m reported GSP China License FX$16m • Transition complete - sales $1,794 m of albumin normalised @CC1 $1,248 m Seqirus • COVID -19 driving strong +44% demand @CC1 • Growth of differentiated products • Manufacturing efficienci
Slide 18: Financial Highlights: CSL Group
Financial Highlights CSL Group For personal use only US$ Millions 1H20 1H21 1H21 Change 1 Reported Reported at CC % Total Revenue 4,911 5,739 5,653 15%1 Gross Profit 2,842 3,472 3,423 20%1 GP margin 57.9% 60.5% 60.6% EBIT 1,632 2,358 2,321 42%1 EBIT margin 33.2% 41.1% 41.1% NPAT 1,248 1,810 1,794 44
Slide 19: Financial Highlights: Segments
Financial Highlights Segments For personal use only CSL Behring Seqirus US$ 1H20 1H21 Change US$ 1H20 1H21 Change 1 1 Millions Reported Reported % at CC Millions Reported Reported % at CC Sales 3,768 4,256 11% Sales 941 1,340 40% Other Other 125 59 (54%) 77 85 7% Revenue Revenue Total Total 3,893 4,
Slide 20: Financial Highlights: Reported Expenses
Financial Highlights Reported Expenses For personal use only 1H20 1H21 Change @ CC 1 R&D US$ Millions • COVID-19 vaccine cost Reported Reported $m % recovery Research & • Portfolio prioritisation 446 427 (24) (5%) Development • FY21 R&D ~10-11% of Sales & Marketing 435 415 (25) (6%) revenue Sales &
Slide 21: Outlook 2H21
Outlook 2H211 For personal use only FY21 result will be heavily skewed to the first half 2H21 CONSIDERATIONS Seqirus • ~80% of sales in 1H, with COGS falling more evenly over the year giving rise to a loss in 2H, consistent with seasonality Behring • Albumin sales now more normalised after the trans
Slide 22: Outlook
Outlook1 For personal use only FUTURE / MID TERM CONSIDERATIONS • Underlying IG demand expected to remain strong • FY22 IG & albumin sales reliant on current plasma collections and cycle times • Collections expected to improve with CSL plasma initiatives and COVID-19 vaccine rollout • As the COVID 1
Slide 23: CSL Contacts
For personal use only CSL Contacts Mark Dehring VP Investor Relations +61 3 9389 3407 mark.dehring@csl.com.au Bernard Ronchi Associate Director, Investor Relations +61 3 9389 3470 bernard.ronchi@csl.com.au Stephen McKeon Associate Director, Investor Relations +61 3 9389 6798 stephen.mckeo
Slide 24: Notes
Notes For personal use only (#) Constant currency removes the impact of Summary NPAT Reported net profit after tax $1,810.0m exchange rate movements to facilitate Translation currency effect (a) $ (15.8m) comparability of operational performance for the Transaction currency effect (b) $ (4.1m) Group